US Stock Futures Mixed Ahead Of Housing-Market Report

Loading...
Loading...
Pre-open movers
US stock futures traded mixed in early pre-market trade. The Empire State manufacturing index for February will be released at 8:30 a.m. ET, while the NAHB housing market index for February will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average declined 11 points to 17,971.00, while the Standard & Poor's 500 index futures fell 2.40 points to 2,091.10. Futures for the Nasdaq 100 index rose 4.75 points to 4,381.75.
A Peek Into Global Markets
European markets were mixed today, with the Spanish Ibex Index rising 0.12%, STOXX Europe 600 Index surging 0.09% and German DAX 30 index dropping 0.33%. French CAC 40 Index slipped 0.16% and London's FTSE 100 Index rose 0.42%. UK's annual inflation shrank to 0.3% in January, versus 0.5% in December. In Asian markets, Japan's Nikkei Stock Average fell 0.10%, Hong Kong's Hang Seng Index rose 0.24% and China's Shanghai Composite Index climbed 0.76%.
Broker Recommendation
Analysts at Cowen & Company downgraded
Sotheby'sBID
from Outperform to Market Perform. Sotheby's shares fell 4.25% to $42.98 in pre-market trading.
Breaking news
  • Starwood Hotels & Resorts Worldwide, Inc. HOT today announced that Frits van Paasschen has resigned by mutual agreement with the Board of Directors as President, Chief Executive Officer and a Director. To read the full news, click here.
  • Campus Crest Communities CCG today announced that its Board of Directors authorized the Company to explore a broad range of strategic, operational and financial alternatives to further enhance shareholder value. To read the full news, click here.
  • Expedia EXPE announced today that it has entered into an agreement with AirAsia Berhad to purchase an additional 25% equity interest of AAE Travel Pte. Ltd., the joint venture formed between the two companies in 2011, for cash consideration of $86.3 million. To read the full news, click here.
  • Hyperion Therapeutics HPTX today announced that it has amicably resolved its disputes, and entered into a completion of phase III clinical trial, option and mutual release agreement with Clal Biotechnology Industries Ltd. CLALF and Yeda Research and Development Company, Ltd. regarding DiaPep277, a product candidate developed by Andromeda Biotech, Ltd., a company which Hyperion acquired from CBI in June 2014. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsCowen & CompanyUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...